By a News Reporter-Staff News Editor at Biotech Week -- A new study on Small Interference RNAs (siRNAs) is now available. According to news reporting from Asahikawa, Japan, by NewsRx journalists, research stated, "P53, a pivotal protein in the apoptotic pathway, has been identified as a mediator of transcriptional responses to ischemia-reperfusion (IR) injury. The characteristics and functional significance of the p53 response in vivo are largely unknown in IR-induced kidney injury."
The news correspondents obtained a quote from the research from Asahikawa Medical University, "Therapeutic opportunities of delivering small interfering RNA (siRNA) via venous injection have gained recognition; however, systemic adverse effects of siRNA therapy should be considered. To prevent IR-induced kidney injury, we tested the efficacy of transarterial administration of siRNA targeting p53 (p53 siRNA). Female C57BL/6 mice underwent unilateral renal artery ischemia for 30 min, followed by reperfusion. siRNA experiments utilized short hairpin (sh) RNA plasmid-based approaches. Transfection of shRNA was performed using cationic polymer transfection reagent. Injection of synthetic p53 shRNA into the left renal artery just after ischemia improved tubular injury, apoptosis, and the swelling of mitochondria in cells of the thick ascending limb of Henle (mTALH) at the outer medullary regions. Staining of upregulated p53 was colocalized with the inducible expression of glycogen synthase kinase-3 beta (GSK-3 beta) at mTALH after IR injury. p53 shRNA inhibited GSK-3 beta expression and restored beta-catenin expression at mTALH. For IR-induced kidney injury, transarterial delivery of p53 siRNA is an effective pharmacological intervention. Targeting siRNA to p53 leads to an attenuation of apoptosis and mitochondrial damage through the downregulation of GSK-3 beta expression and upregulation of beta-catenin."
According to the news reporters, the research concluded: "Local delivery of vectors such as p53 siRNA through a transaortic catheter is clinically useful in reducing the adverse effect of siRNA-related therapy."
For more information on this research see: Silencing of p53 RNA through transarterial delivery ameliorates renal tubular injury and downregulates GSK-3 beta expression after ischemia-reperfusion injury. American Journal of Physiology-Renal Physiology, 2013;305(11):F1617-F1627. American Journal of Physiology-Renal Physiology can be contacted at: Amer Physiological Soc, 9650 Rockville Pike, Bethesda, MD 20814, USA (see also Small Interference RNAs (siRNAs)).
Our news journalists report that additional information may be obtained by contacting T. Fujino, Asahikawa Med Univ, Dept. of Internal Med, Cardiovasc Resp & Neurol Div, Asahikawa, Hokkaido 0788510, Japan. Additional authors for this research include S. Muhib, N. Sato and N. Hasebe.
Keywords for this news article include: Asia, Japan, Kidney, Therapy, Genetics, Ischemia, p53 Gene, Asahikawa, Nephrology, Reperfusion, Medical Devices, Blood Transfusion, Transfusion Medicine, Small Interference RNAs (siRNAs)
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC